Changing Views toward mRNA based Covid Vaccines in the Scientific Literature: 2020 - 2024

Author:

Thoene Michael Allen1ORCID

Affiliation:

1. Department of Medical Biology, School of Public Health, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland

Abstract

IntroductionBefore the global Covid-19 pandemic caused by the SARS-CoV-2 virus, mRNA based vaccines had never been administered to the public outside of a single clinical trial that was not completed at the time. However, within the space of 9 months these experimental vaccines were administered to millions through an emergency use authorization (EUA).AimThe aim of this article is to raise awareness that medical science can be biased due to social and economic influences, especially during high stress epochs in history. Scientists should be conscious of always being objective and skeptical regardless of what is happening in the wider world.Material and methodsA literature survey was performed examining the reporting of severe adverse events (SAEs) in articles published between 2020 and 2024.Results and discussionFrom 2020 to 2024, the literature has gone from claiming there are absolutely no SAEs from mRNA based vaccines (2020/2021) to an acknowledgment of a significant number of various SAEs (2023/2024); including but not limited to neurological complications, myocarditis, pericarditis and thrombosis.ConclusionsThe early scientific literature was biased, so as not to report SAEs, due to social and political concerns and overwhelming corporate greed. Only in the last year have scientists been able to publish articles that acknowledge a high number of SAEs linked to mRNA based vaccines. This should act as a warning that science should be completely objective when evaluating health risks, but can often be influenced by social and economic considerations.

Publisher

Collegium Medicum, University of Warmia and Mazury

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3